Overview

Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma （ARISE）

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, controlled, phase II study.
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Cancer Hospital
Collaborator:
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Treatments:
Carboplatin
Paclitaxel